Organon
Commercializes women's health medicines, biosimilars, and established brands.
Something off on this page? Send us feedback.
Profile
Commercializes women's health medicines, biosimilars, and established brands through an international footprint. A Merck spin-off, it serves conditions affecting women uniquely, disproportionately, or differently.
Women's Health, biosimilars, and Established Brands form the three business components. The portfolio combines medicines and solutions for conditions that affect women uniquely, disproportionately, or differently with mature branded medicines and biosimilars.
Built through the 2021 separation from Merck, the company operates with an international commercial footprint and roots in Organon's hormonal-medicine lineage. Targeted additions included Dermavant and its VTAMA dermatology therapy; JADA was sold to Laborie in 2026.
Operations are shaped by a pending Sun Pharma merger that requires stockholder, antitrust, foreign-investment, and other closing approvals. OGN remains NYSE-listed unless and until the transaction closes.
Company facts
Key statistics
Year to date +90.1% · Average volume (30d) 2.8M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Apr 29, 2026 | BNP Paribas | Downgrade | Outperform | Neutral | ||
| Apr 28, 2026 | Piper Sandler | Upgrade | Underweight | Neutral | ||
| Apr 27, 2026 | Piper Sandler | Target | $5 | $14 | ||
| Apr 10, 2026 | BNP Paribas | Target | $12 | |||
| Feb 24, 2026 | Barclays | Reiterate | Underweight | $7.50 | $8 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026Q2 FY26 | $0.91 | $0.41 | −54.9% | $1.57B | $1.56B | −0.8% | 0.00% |
| Apr 30, 2026Q1 FY26 | $0.83 | $0.71 | −14.5% | $1.49B | $1.46B | −1.9% | +0.30% |
| Feb 12, 2026Q4 FY25 | $0.73 | $0.63 | −13.7% | $1.53B | $1.51B | −1.8% | +4.67% |
| Nov 10, 2025Q3 FY25 | $0.93 | $1.01 | +8.6% | $1.52B | $1.60B | +5.3% | −2.46% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.51B | $1.59B | $1.60B | $1.51B | $1.46B | $1.56B | |
| Gross profit | $841.0M | $874.0M | $857.0M | $759.0M | $783.0M | $847.0M | |
| Operating income | $325.0M | $326.0M | $358.0M | $235.0M | $266.0M | $323.0M | |
| Net income | $87.0M | $145.0M | $160.0M | −$205.0M | $146.0M | $108.0M | |
| Diluted EPS | $0.33 | $0.56 | $0.61 | −$0.79 | $0.55 | $0.40 | |
| Gross margin | 55.6% | 54.8% | 53.5% | 50.4% | 53.6% | 54.4% | |
| Operating margin | 21.5% | 20.5% | 22.3% | 15.6% | 18.2% | 20.7% |
Fiscal years (4-quarter sums)FY21 $6.33B · FY22 $6.17B · FY23 $6.26B · FY24 $6.40B · FY25 $6.22B
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $1.13B · Total debt $8.55B · Total assets $13.18B · Shareholders' equity $1.01B
Dividends
Last cut to $0.02 from $0.28 in May 2025. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 14, 2026 | Aug 14 | Sep 10 | $0.02 | |
| May 11, 2026 | May 11 | Jun 11 | $0.02 | |
| Feb 23, 2026 | Feb 23 | Mar 12 | $0.02 | |
| Nov 20, 2025 | Nov 20 | Dec 11 | $0.02 | |
| Aug 15, 2025 | Aug 15 | Sep 11 | $0.02 | |
| May 12, 2025 | May 12 | Jun 12 | $0.02 | cut from $0.28 |
| Feb 24, 2025 | Feb 24 | Mar 13 | $0.28 | |
| Nov 12, 2024 | Nov 12 | Dec 12 | $0.28 |
Ownership
Shares outstanding 262.61M · Float 261.09M · 99.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 32.06M | 12.21% | 13F | Aug 7, 2026 |
| Pentwater Capital Management LP | 18.10M | 6.90% | 13G | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 15.13M | 5.76% | 13F | Aug 13, 2026 |
| Vanguard Capital Management LLC | 11.91M | 4.54% | 13F | Aug 13, 2026 |
| State Street Corp | 9.66M | 3.68% | 13F | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 5, 2026 | Juliana Papa Drinane | officer: Head of Mfg & Supply | −14,761 | $13.57 |
| May 6, 2026 | Lynette Holzbaur | officer: SVP and Corporate Controller | +26,448 | $13.35 |
| May 6, 2026 | Lynette Holzbaur | officer: SVP and Corporate Controller | −26,448 | $13.35 |
| Nov 12, 2025 | Carrie Smith Cox | director, officer: Executive Chair | +65,400 | $7.67 |
Peers
- AbbVie
Reference biologic in Organon's largest biosimilar franchise
- Amgen
Reference biologics in immunology, bone disease, and oncology
- Teva (ADR)
Generics and biosimilars in price-sensitive drug markets
- Incyte
Topical immunology therapy for atopic dermatitis
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Organon | $13.76 | 0.00% | $3.61B | 17.9 | 3.9 | 0.6 | −2.3% |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Amgen | $430.27 | −0.49% | $233.38B | 26.9 | 18.4 | 6.1 | +9.7% |
| Teva (ADR) | $36.30 | −0.36% | $42.44B | 60.7 | 12.9 | 2.5 | −0.8% |
| Incyte | $124.37 | −0.03% | $25.21B | 15.8 | 43.0 | 4.3 | +37.7% |
| Median | 43.8 | 17.6 | 5.2 | +9.9% |